The epilepsy treatment gap in Africa exceeds 80% — four out of five people with ...
Africa Trials
73
US Trials
1,017
Gap Ratio
14x
Nations
54
Key Finding
Africa hosted 73 epilepsy trials versus 1,017 in the United States, a 14-fold disparity in research investment.
Regional Comparison
Distribution Analysis
Inequality Profile
Temporal & Structural
Why It Matters
The epilepsy treatment gap in Africa exceeds 80% — four out of five people with epilepsy receive no treatment — yet the trial pipeline for affordable antiepileptic regimens is nearly empty.
The Evidence 138 words · target 156
In the burden-versus-investment landscape of African health research, does the distribution of epilepsy trials across African nations reveal a systematic research gap? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation. Africa hosted 73 epilepsy trials (0.3% of its portfolio) compared to 1,017 in the United States, yielding a 0.0-fold disparity in per-population investment. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa. Interpretation is limited by the use of a single registry and the absence of non-English trial databases.
Sentence Structure
Question
In the burden-versus-investment landscape of African health research, does the distribution of epilepsy trials across African nations reveal a systematic research gap?
Dataset
This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.
Method
gov through April 2026.
Primary Result
Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation.
Robustness
Africa hosted 73 epilepsy trials (0.
Interpretation
3% of its portfolio) compared to 1,017 in the United States, yielding a 0.
Boundary
0-fold disparity in per-population investment.
Extra
Temporal analysis showed 17.
Extra
1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.
Extra
These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa.
Extra
Interpretation is limited by the use of a single registry and the absence of non-English trial databases.